Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lü, Shucai Zhang, Shundong Cang et al.|Journal of Thoracic Oncology|2022Cited by 25
Identification and validation of an immunotherapeutic signature for colon cancer based on the regulatory patterns of ferroptosis and their association with the tumor microenvironmentYong Liu, Zunnan Huang, Junzhang Zhao et al.|Biochimica et Biophysica Acta (BBA) - Molecular Cell Research|2024Cited by 5